Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Eltrombopag olamine

September 13, 2016

## Non-proprietary name

Eltrombopag olamine

## Safety measure

Precautions should be revised in the package insert.

In the Precautions of dosage and administration section regarding the concomitant use with formulations containing multivalent cations etc., the following text should be revised (underlined parts are revised):

Blood concentration of this drug decreases when concomitantly used with products such as antacids, milk products, and formulations containing multivalent cations (iron, calcium, aluminum, magnesium, selenium, zinc, etc.). Consumption of these products should be avoided 4 hours before <u>and 2 hours after</u> receiving this drug.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>